Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 845

Sort by

Sort Order Select

Journal Articles

Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study

Blood (2019) 134 (Supplement_1): 232.

https://doi.org/10.1182/blood-2019-123966

Published: 2019

Journal Articles

Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, MD, Patrick J. Stiff, MD, Emad Ibrahim, MBBCh, MD, Anusha Vallurupalli, MBBS, Elizabeth H. Cull, MD, Damian J. Green, MD, Kate Oliver, BS, Jarrod Longcor

Blood (2019) 134 (Supplement_1): 144.

https://doi.org/10.1182/blood-2019-131014

Published: 2019

Journal Articles

Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integrated Results from a Phase 1/2a and an Ongoing Phase 2b

Jessica K. Altman, Tsila Zuckerman, MD, Olga Frankfurt, MD, Selina M. Luger, MD FRCPC, Dale L. Bixby, MD, Vamsi Kota, MBBS, Micah M. Burch, Ofir Wolach, Itai Levi, MD, Anna Gourevitch, Ron Ram, MD, Liat Flaishon, Shoshi Tessler, Stela Gengrinovitch, Ruth Ben Yakar, Jacob M. Rowe, MB, BS

Blood (2019) 134 (Supplement_1): 179.

https://doi.org/10.1182/blood-2019-124330

Published: 2019

Journal Articles

Azacitidine for Post-Remission Therapy in Elderly Patients with Acute Myeloid Leukemia : Final Results of the Qoless AZA-Amle Randomized Trial

Blood (2019) 134 (Supplement_1): 117.

https://doi.org/10.1182/blood-2019-125562

Published: 2019

Journal Articles

Decitabine As First Line Treatment in Acute Myeloid Leukemia of the Elderly: Real-Life Experience from a Single Center

Eleni Bouronikou, Eleni Georgiadi, George Vassilopoulos, MD PhD

Blood (2019) 134 (Supplement_1): 5137.

https://doi.org/10.1182/blood-2019-123028

Published: 2019

Journal Articles

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

Nirav N. Shah, MD, Amrita Y. Krishnan, MD, Nina D. Shah, MD, John M Burke, MD, Jason M. Melear, MD, Alexander I. Spira, PhD MD FACP, Leslie L. Popplewell, MD FRCPA, Charalambos B. Andreadis, MD, Saurabh Chhabra, MD, Jeff P. Sharman, MD, Jonathan L. Kaufman, MD, Jonathon B. Cohen, MDMS, Ruben Niesvizky, MD, Thomas G. Martin, III, MD, Clifford DiLea, RPh, Pharm.D., Jason Kuriakose, Shannon L. Matheny, PhD, John P. Leonard, MD, Arturo Molina, MDMS, FACP

Blood (2019) 134 (Supplement_1): 5329.

https://doi.org/10.1182/blood-2019-122754

Published: 2019

Journal Articles

Decitabine Can Improve the Efficacy of Second-Line Chemotherapy in Relapsed or Refractory Diffuse Llarge B Cell Lymphoma

Xudong Zhang, Junxia Hu, Qingjiang Chen, Mingzhi Zhang, MD PhD, Ken H. Young

Blood (2019) 134 (Supplement_1): 5221.

https://doi.org/10.1182/blood-2019-128424

Published: 2019

Journal Articles

Novel Pathogenic Genes and Rare Mutations of Congenital Factor V Deficiency: A Case Report

Haixia Guo, MD PhD

Blood (2019) 134 (Supplement_1): 4920.

https://doi.org/10.1182/blood-2019-126350

Published: 2019

Journal Articles

Outcomes in Heparin-Induced Thrombocytopenia Managed with Direct Oral Anticoagulants

Nwabundo Anusim, MD, Filip Ionescu, MD, Anish S Konde, MD, Vishal Jindal, MD, Ruby Gupta, MD, Marianne Terese Huben, DO, Susanna Gaikazian, MD, Ishmael Jaiyesimi, DO, MS

Blood (2019) 134 (Supplement_1): 4975.

https://doi.org/10.1182/blood-2019-129485

Published: 2019

Journal Articles

Biodistribution and Efficacy of L-Annamycin in a Novel Imageable AML Mouse Model

Rafal Zielinski, PhD, Krzysztof Grela, PhD, Stanislaw Skora, PhD, Rodrigo Jacamo, PhD, Izabela Fokt, PhD, Matthew Sander, Magdalena Remiszewski, PhD, Edward Felix, PhD, Meenakshi Shanmugasundaram, Malgorzata Anna Zal, MSc, Michael Andreeff, MD PhD, Waldemar Priebe, PhD, Tomasz Zal, PhD

Blood (2019) 134 (Supplement_1): 5150.

https://doi.org/10.1182/blood-2019-131977

Published: 2019

Journal Articles

Blinatumomab and Venetoclax for Minimal Residual Disease Relapse in Acute Lymphoblastic Leukemia

Gregorio Campos-Cabrera, MD, Noe-Benjamin Vega-Tapia, MD, Virgina Campos-Cabrera, QFB EBC, Salvador Campos-Cabrera, MD, Jose-Luis Campos-Villagomez, MD, Esther Mendez-Garcia, MD

Blood (2019) 134 (Supplement_1): 5128.

https://doi.org/10.1182/blood-2019-127296

Published: 2019

Journal Articles

A Phase 2 Study of MT-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Daniel O. Persky, MD, Vasile Musteata, MD PhD, Mamia Zodelava, MD, Tetiana Perekhrestenko, MD PhD, Adolfo E Diaz, MD, Troy H. Guthrie, Jr., MD, Thomas Strack, MD, Christine Burnett, Sarah Wilson, CCRA, Tara Baetz, MD FRCPC

Blood (2019) 134 (Supplement_1): 5324.

https://doi.org/10.1182/blood-2019-128604

Published: 2019

Journal Articles

Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Ulrich Jaeger, MD, Nina Worel, MD, Joseph P. McGuirk, DO, Peter A. Riedell, MD, Isabelle Fleury, MD, Peter Borchmann, MD, Jufen Chu, PhD, Ahmed M Abdelhady, PhD, Alessandra Forcina, MD, Lida Bubuteishvili Pacaud, MD, Edmund K. Waller, PhDMD

Blood (2019) 134 (Supplement_1): 5325.

https://doi.org/10.1182/blood-2019-129120

Published: 2019

Journal Articles

Novel Cellular Immunotherapy Using Allogeneic Vγ9/δ2-T Cells Gene-Modified to Express HTLV-1 P40Tax-Specific TCR for the Treatment of Adult T Cell Leukemia

Hiroshi Fujiwara, MD PhD, Satoshi Okumura, Yoshihiro Miyahara, Linan Wan, Isao Tawara, MD PhD, Tatsuro Jo, MD PhD, Yuetsu Tanaka, PhD, Yoshimasa Tanaka, PhD, Hiroaki Ikeda, Hiroshi Shiku

Blood (2019) 134 (Supplement_1): 3216.

https://doi.org/10.1182/blood-2019-122412

Published: 2019

Journal Articles

Innate Immune Mechanism of Hemarthrosis in Hemophilia-a Mice

Tomasz W. Kaminski, PharmD, Egemen Tutuncuoglu, MSc, Margaret V. Ragni, MD MPH, Mark T Gladwin, MD, Prithu Sundd, PhD

Blood (2019) 134 (Supplement_1): 1043.

https://doi.org/10.1182/blood-2019-130471

Published: 2019

Journal Articles

The Effect of Crizanlizumab Plus Standard of Care (SoC) Versus Soc Alone on Renal Function in Patients with Sickle Cell Disease and Chronic Kidney Disease: A Randomized, Multicenter, Open-Label, Phase II Study (STEADFAST)

Kenneth I. Ataga, MD, Santosh L. Saraf, MD, Vimal K. Derebail, MD, Claire C. Sharpe, Adlette Inati, MD, Jeffrey D. Lebensburger, DO, MSPH, Laurie DeBonnett, MD, Shirong Zhang, Pablo Bartolucci, MD PhD

Blood (2019) 134 (Supplement_1): 1018.

https://doi.org/10.1182/blood-2019-124823

Published: 2019

Journal Articles

Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis

Blood (2019) 134 (Supplement_1): 558.

https://doi.org/10.1182/blood-2019-131217

Published: 2019

Journal Articles

First-in-human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A

Steven Pipe, MD, Michael Becka, Elke Detering, Konstantina Vanevski, Toshko Lissitchkov

Blood (2019) 134 (Supplement_1): 4630.

https://doi.org/10.1182/blood-2019-125764

Published: 2019

Journal Articles

A Phase 1a/1b Trial of ST-001, a Fenretinide Phospholipid Suspension for 4-Hour Intravenous Infusion in Relapsed/Refractory T-Cell Non-Hodgkin's Lymphoma

Ayad Al-Katib, MD, Timothy M. Kuzel, MD, Ralph Parchment, PhD

Blood (2019) 134 (Supplement_1): 4041.

https://doi.org/10.1182/blood-2019-127278

Published: 2019

Journal Articles

Phase 2 Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4032.

https://doi.org/10.1182/blood-2019-121723

Published: 2019

NARROW

Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study

Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integrated Results from a Phase 1/2a and an Ongoing Phase 2b

Azacitidine for Post-Remission Therapy in Elderly Patients with Acute Myeloid Leukemia : Final Results of the Qoless AZA-Amle Randomized Trial

Decitabine As First Line Treatment in Acute Myeloid Leukemia of the Elderly: Real-Life Experience from a Single Center

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

Decitabine Can Improve the Efficacy of Second-Line Chemotherapy in Relapsed or Refractory Diffuse Llarge B Cell Lymphoma

Novel Pathogenic Genes and Rare Mutations of Congenital Factor V Deficiency: A Case Report

Outcomes in Heparin-Induced Thrombocytopenia Managed with Direct Oral Anticoagulants

Biodistribution and Efficacy of L-Annamycin in a Novel Imageable AML Mouse Model

Blinatumomab and Venetoclax for Minimal Residual Disease Relapse in Acute Lymphoblastic Leukemia

A Phase 2 Study of MT-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Novel Cellular Immunotherapy Using Allogeneic Vγ9/δ2-T Cells Gene-Modified to Express HTLV-1 P40Tax-Specific TCR for the Treatment of Adult T Cell Leukemia

Innate Immune Mechanism of Hemarthrosis in Hemophilia-a Mice

The Effect of Crizanlizumab Plus Standard of Care (SoC) Versus Soc Alone on Renal Function in Patients with Sickle Cell Disease and Chronic Kidney Disease: A Randomized, Multicenter, Open-Label, Phase II Study (STEADFAST)

Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis

First-in-human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A

A Phase 1a/1b Trial of ST-001, a Fenretinide Phospholipid Suspension for 4-Hour Intravenous Infusion in Relapsed/Refractory T-Cell Non-Hodgkin's Lymphoma

Phase 2 Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only